Sage Therapeutics
215 First Street
Cambridge
MA
02142
United States
Tel: 617-299-8380
Website: https://www.sagerx.com/
About Sage Therapeutics
Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner.
Stock Symbol:
SAGE
387 articles about Sage Therapeutics
-
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus
7/22/2014
-
SAGE Therapeutics Announces Full Exercise Of Over-Allotment Option
7/21/2014
-
SAGE Therapeutics Announces Pricing Of Initial Public Offering
7/18/2014
-
Cambridge's SAGE Therapeutics Ups Proposed IPO Deal Size
7/17/2014
-
Cambridge-Based SAGE Therapeutics Readies $69 Million IPO Pitch To Develop CNS Drugs
6/18/2014
-
SAGE Therapeutics Appoints James M. Frates To The Company’s Board Of Directors
6/10/2014
-
SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data At Epilepsy Pipeline Conference
6/5/2014
-
Ligand Pharmaceuticals Inc. Earns Milestone From SAGE Therapeutics For SAGE-547
5/12/2014
-
SAGE Therapeutics Appoints Thomas D. Anderson As Chief Commercial Strategy Officer
5/5/2014
-
SAGE Therapeutics Appoints Howard H. Pien To The Company’s Board Of Directors
4/1/2014
-
SAGE Therapeutics Initiates Phase 1/2 Trial Of SAGE-547 In Status Epilepticus
3/27/2014
-
Cambridge's SAGE Therapeutics Nabs $38 Million For CNS Drugs
3/13/2014
-
SAGE Therapeutics To Present At The 2014 Leerink Swann and Company Global Healthcare Conference
2/5/2014
-
SAGE Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
1/6/2014
-
SAGE Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
1/6/2014
-
SAGE Therapeutics Announces Collaboration With Washington University To Develop Novel GABA Receptor Small Molecules
12/20/2013
-
SAGE Therapeutics Presents New Data Identifying Highly Selective, Oral Compounds And Novel Approach For The Treatment Of Chronic Epilepsies
12/9/2013
-
SAGE Therapeutics’s Novel Approach To Treatment Of CNS Disorders To Be Highlighted At Leading Industry And Scientific Conferences
11/18/2013
-
SAGE Therapeutics’s Novel Approach To Treatment Of CNS Disorders To Be Highlighted At Leading Industry And Scientific Conferences
11/18/2013
-
SAGE Therapeutics Presents New Mechanistic Insights On Novel Approach To NMDA Receptor Modulation
11/13/2013